A long-term copper exposure on freshwater ecosystem using lotic mesocosms: Individual and population responses of three-spined sticklebacks (Gasterosteus aculeatus)

Three-spined stickleback (Gasterosteus aculeatus) was used as the highest trophic level predator in an outdoor mesocosm study assessing the effect of environmentally realistic copper concentration (0, 5, 25 and 75 μg L−1) over 18 months of continuous exposure. Condition factor, organosomatic indices (HIS, GSI and SSI) as well as copper bioaccumulation in the liver were measured at 15 days, 2, 4, 6, 10, 14 and 18 months after the beginning of the contamination. Population monitoring was realised after 6 and 18 months of contamination, allowing two reproduction periods to be measured. Results showed that condition factor was affected at medium and high copper concentrations and HSI was sporadically affected in all copper exposure, depending on the sex of the fish. GSI did not show any significant differences and SSI was lowered in the medium and high copper levels. Bioaccumulation was significantly different in males and females and fluctuated with season. A negative correlation was observed between copper bioaccumulation in the liver and fish size and a positive correlation with nominal copper concentration in the water was found. There was a negative correlation between condition factor, organosomatic indices and bioaccumulation in the liver. Population monitoring showed a significantly higher fish mean length after 6 months and a higher abundance after 18 months of exposure at the highest copper level. We conclude that indirect effects such as food and habitat availability or lower predation pressure on eggs and juveniles might have led to higher stickleback population abundances at the highest copper level. This highlights the need to study all the trophic levels when monitoring ecosystem health. Considering the population and the individual responses after 18 months of copper exposure, the NOEC for three-spined sticklebacks was 25 μg L−1 (or 20 μg L−1 if we consider the average effective concentration), with a LOEC of 75 μg L−1 (or 57 μg L−1, AEC)

Delayed-Onset Hemolytic Anemia in Patients with Travel-Associated Severe Malaria Treated with Artesunate, France, 2011–2013

French Artesunate Working GroupInternational audienceArtesunate is the most effective treatment for severe malaria. However, delayed-onset hemolytic anemia has been observed in ≈20% of travelers who receive artesunate, ≈60% of whom require transfusion. This finding could discourage physicians from using artesunate. We prospectively evaluated a cohort of 123 patients in France who had severe imported malaria that was treated with artesunate; our evaluation focused on outcome, adverse events, and postartesunate delayed-onset hemolysis (PADH). Of the 123 patients, 6 (5%) died. Overall, 97 adverse events occurred. Among the 78 patients who received follow-up for >8 days after treatment initiation, 76 (97%) had anemia, and 21 (27%) of the 78 cases were recorded as PADH. The median drop in hemoglobin levels was 1.3 g/dL; 15% of patients with PADH had hemoglobin levels of <7 g/dL, and 1 required transfusion. Despite the high incidence of PADH, the resulting anemia remained mild in 85% of cases. This reassuring result confirms the safety and therapeutic benefit of artesunate

High-resolution imaging of the Pyrenees and Massif Central from the data of the PYROPE and IBERARRAY portable array deployments

International audienceThe lithospheric structures beneath the Pyrenees, which holds the key to settle long-standing controversies regarding the opening of the Bay of Biscay and the formation of the Pyrenees, are still poorly known. The temporary PYROPE and IBERARRAY experiments have recently filled a strong deficit of seismological stations in this part of western Europe, offering a new and unique opportunity to image crustal and mantle structures with unprecedented resolution. Here we report the results of the first tomographic study of the Pyrenees relying on this rich data set. The important aspects of our tomographic study are the precision of both absolute and relative traveltime measurements obtained by a nonlinear simulated annealing waveform fit and the detailed crustal model that has been constructed to compute accurate crustal corrections. Beneath the Massif Central, the most prominent feature is a widespread slow anomaly that reflects a strong thermal anomaly resulting from the thinning of the lithosphere and upwelling of the asthenosphere. Our tomographic images clearly exclude scenarios involving subduction of oceanic lithosphere beneath the Pyrenees. In contrast, they reveal the segmentation of lithospheric structures, mainly by two major lithospheric faults, the Toulouse fault in the central Pyrenees and the Pamplona fault in the western Pyrenees. These inherited Hercynian faults were reactivated during the Cretaceous rifting of the Aquitaine and Iberian margins and during the Cenozoic Alpine convergence. Therefore, the Pyrenees can be seen as resulting from the tectonic inversion of a segmented continental rift that was buried by subduction beneath the European plate

Nutrition for the ageing brain: towards evidence for an optimal diet

As people age they become increasingly susceptible to chronic and extremely debilitating brain diseases. The precise cause of the neuronal degeneration underlying these disorders, and indeed normal brain ageing remains however elusive. Considering the limits of existing preventive methods, there is a desire to develop effective and safe strategies. Growing preclinical and clinical research in healthy individuals or at the early stage of cognitive decline has demonstrated the beneficial impact of nutrition on cognitive functions. The present review is the most recent in a series produced by the Nutrition and Mental Performance Task Force under the auspice of the International Life Sciences Institute Europe (ILSI Europe). The latest scientific advances specific to how dietary nutrients and non-nutrient may affect cognitive ageing are presented. Furthermore, several key points related to mechanisms contributing to brain ageing, pathological conditions affecting brain function, and brain biomarkers are also discussed. Overall, findings are inconsistent and fragmented and more research is warranted to determine the underlying mechanisms and to establish dose-response relationships for optimal brain maintenance in different population subgroups. Such approaches are likely to provide the necessary evidence to develop research portfolios that will inform about new dietary recommendations on how to prevent cognitive decline

Deir el-Médina (2022)

Ce rapport présente les travaux réalisés en 2022 sur le site de Deir el-Médina par la mission archéologique de l’Ifao, en partenariat avec plusieurs institutions européennes, américaines et égyptiennes. Le Comité permanent du MoTA a approuvé le plan d’actions proposé, à savoir l’étude et la restauration de plusieurs monuments, dont la chapelle d’Amennakhte, les tombes TT 8 de Khâ, TT 216 de Neferhotep, TT 217 d’Ipouy, TT 265 d’Amenemipet et le temple ptolémaïque, ainsi que l’étude du mobilier..

Nutrition for the ageing brain: towards evidence for an optimal diet

As people age they become increasingly susceptible to chronic and extremely debilitating brain diseases. The precise cause of the neuronal degeneration underlying these disorders, and indeed normal brain ageing remains however elusive. Considering the limits of existing preventive methods, there is a desire to develop effective and safe strategies. Growing preclinical and clinical research in healthy individuals or at the early stage of cognitive decline has demonstrated the beneficial impact of nutrition on cognitive functions. The present review is the most recent in a series produced by the Nutrition and Mental Performance Task Force under the auspice of the International Life Sciences Institute Europe (ILSI Europe). The latest scientific advances specific to how dietary nutrients and non-nutrient may affect cognitive ageing are presented. Furthermore, several key points related to mechanisms contributing to brain ageing, pathological conditions affecting brain function, and brain biomarkers are also discussed. Overall, findings are inconsistent and fragmented and more research is warranted to determine the underlying mechanisms and to establish dose-response relationships for optimal brain maintenance in different population subgroups. Such approaches are likely to provide the necessary evidence to develop research portfolios that will inform about new dietary recommendations on how to prevent cognitive decline

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

Objectives The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. Methods Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. Results On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P = 0.0455) and T215Y (P = 0.0455). Conclusions In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performe

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Life-threatening `breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS- CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; however, their contribution to hypoxemic breakthrough cases in vaccinated people remains unknown. Here, we studied a cohort of 48 individuals ( age 20-86 years) who received 2 doses of an mRNA vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Antibody levels to the vaccine, neutralization of the virus, and auto- Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal antibody response to the vaccine. Among them, ten (24%) had auto-Abs neutralizing type I IFNs (aged 43-86 years). Eight of these ten patients had auto-Abs neutralizing both IFN-a2 and IFN-., while two neutralized IFN-omega only. No patient neutralized IFN-ss. Seven neutralized 10 ng/mL of type I IFNs, and three 100 pg/mL only. Seven patients neutralized SARS-CoV-2 D614G and the Delta variant (B.1.617.2) efficiently, while one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only 100 pg/mL of type I IFNs neutralized both D61G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating antibodies capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a significant proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Background Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis looking for Huntington's disease modifiers, but is hard to define and not always available. Therefore, we aimed to generate a novel measure of disease progression and to identify genetic markers associated with this progression measure. Methods We generated a progression score on the basis of principal component analysis of prospectively acquired longitudinal changes in motor, cognitive, and imaging measures in the 218 indivduals in the TRACK-HD cohort of Huntington's disease gene mutation carriers (data collected 2008–11). We generated a parallel progression score using data from 1773 previously genotyped participants from the European Huntington's Disease Network REGISTRY study of Huntington's disease mutation carriers (data collected 2003–13). We did a genome-wide association analyses in terms of progression for 216 TRACK-HD participants and 1773 REGISTRY participants, then a meta-analysis of these results was undertaken. Findings Longitudinal motor, cognitive, and imaging scores were correlated with each other in TRACK-HD participants, justifying use of a single, cross-domain measure of disease progression in both studies. The TRACK-HD and REGISTRY progression measures were correlated with each other (r=0·674), and with age at onset (TRACK-HD, r=0·315; REGISTRY, r=0·234). The meta-analysis of progression in TRACK-HD and REGISTRY gave a genome-wide significant signal (p=1·12 × 10−10) on chromosome 5 spanning three genes: MSH3, DHFR, and MTRNR2L2. The genes in this locus were associated with progression in TRACK-HD (MSH3 p=2·94 × 10−8 DHFR p=8·37 × 10−7 MTRNR2L2 p=2·15 × 10−9) and to a lesser extent in REGISTRY (MSH3 p=9·36 × 10−4 DHFR p=8·45 × 10−4 MTRNR2L2 p=1·20 × 10−3). The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis (p=1·58 × 10−8), and encodes an aminoacid change (Pro67Ala) in MSH3. In TRACK-HD, each copy of the minor allele at this SNP was associated with a 0·4 units per year (95% CI 0·16–0·66) reduction in the rate of change of the Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score, and a reduction of 0·12 units per year (95% CI 0·06–0·18) in the rate of change of UHDRS Total Functional Capacity score. These associations remained significant after adjusting for age of onset. Interpretation The multidomain progression measure in TRACK-HD was associated with a functional variant that was genome-wide significant in our meta-analysis. The association in only 216 participants implies that the progression measure is a sensitive reflection of disease burden, that the effect size at this locus is large, or both. Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation

Quelle efficacité pour la prévention des addictions chez les adolescents ?

Dans le cadre d’une réflexion sur les assuétudes chez les jeunes, le Centre Local de Promotion de la Santé du Brabant Wallon organise des tables-rondes avec divers acteurs. L’Unité RESO s’est vue solliciter afin de réaliser un dossier technique visant à documenter leur prochaine rencontre et devant leur permettre de dégager des bonnes pratiques et des critères de qualité pour la prévention des « assuétudes » chez les adolescent